Adamis Pharmaceuticals (ADMP) stock price, revenue, and financials

Adamis Pharmaceuticals market cap is $68.8 m, and annual revenue was $15.09 m in FY 2018

$68.8 M

ADMP Mkt cap, 10-Jun-2019

$5.8 M

Adamis Pharmaceuticals Revenue Q2, 2019
Adamis Pharmaceuticals Gross profit (Q2, 2019)2.1 M
Adamis Pharmaceuticals Gross profit margin (Q2, 2019), %36.4%
Adamis Pharmaceuticals Net income (Q2, 2019)-7.7 M
Adamis Pharmaceuticals EBIT (Q2, 2019)-7.7 M
Adamis Pharmaceuticals Cash, 30-Jun-20194.1 M

Adamis Pharmaceuticals Income Statement

Annual

USDFY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

Revenue

6.5m13.1m15.1m

Cost of goods sold

4.9m7.4m9.8m

Gross profit

1.6m5.7m5.3m

Gross profit Margin, %

25%43%35%

R&D expense

1.0m4.8m9.7m7.5m18.8m

General and administrative expense

3.4m9.0m17.1m22.8m25.9m

Operating expense total

4.4m13.9m26.8m30.3m44.7m

EBIT

(4.4m)(13.9m)(25.2m)(24.8m)(39.5m)

EBIT margin, %

(389%)(190%)(262%)

Interest expense

8.6m214.4k231.3k157.8k

Interest income

9.3k102.2k245.4k

Income tax expense

4.6m339.4k369.3k

Net Income

(8.2m)(13.6m)(19.4m)(25.5m)(39.0m)

Adamis Pharmaceuticals Balance Sheet

Annual

USDFY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

Cash

5.4m4.1m4.1m17.3m19.3m

Accounts Receivable

805.4k830.1k1.2m

Inventories

14.5k71.0k942.1k1.8m3.3m

Current Assets

4.2m21.5m25.8m

PP&E

6.6m9.9m

Goodwill

7.6m7.6m7.6m

Total Assets

15.1m12.1m37.8m51.4m58.4m

Accounts Payable

671.0k497.8k2.2m2.9m4.2m

Short-term debt

383.3k

Current Liabilities

8.6m8.8m11.6m

Long-term debt

2.6m

Total Debt

383.3k2.6m

Total Liabilities

2.9m2.7m12.5m11.9m11.7m

Additional Paid-in Capital

58.3m78.3m113.7m153.5m199.7m

Retained Earnings

(46.1m)(69.0m)(88.5m)(114.0m)(153.0m)

Total Equity

9.3m25.3m39.5m46.7m

Debt to Equity Ratio

0.1 x

Debt to Assets Ratio

0.1 x

Financial Leverage

1.3 x1.5 x1.3 x1.2 x

Quarterly

USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019

Cash

119.6k4.7m2.1m5.9m11.2m8.5m6.3m4.4m417.1k7.8m399.5k10.7m23.3m9.1m3.4m32.0m9.2m4.1m

Accounts Receivable

744.7k595.6k1.2m1.2m1.0m980.8k1.2m1.2m1.8m2.9m

Inventories

1.2m1.1m914.2k950.0k996.1k2.3m2.6m3.2m3.4m2.9m

Current Assets

2.2m6.0m11.3m8.5m6.4m5.0m2.6m10.7m26.5m13.9m8.7m37.7m17.5m12.0m

PP&E

4.8m5.2m5.8m7.1m8.5m9.2m11.3m11.5m

Goodwill

2.2m2.2m7.6m7.6m7.6m7.6m7.6m7.6m7.6m7.6m

Total Assets

3.5m14.8m11.6m15.1m20.0m16.9m14.6m12.7m29.4m36.7m33.7m43.9m56.3m43.8m39.4m70.2m52.7m47.1m

Accounts Payable

2.3m1.7m547.7k750.0k977.2k498.0k408.8k1.5m4.2m1.7m2.7m1.9m1.8m2.3m5.2m3.5m4.0m4.3m

Short-term debt

561.3k581.4k4.5m4.3m2.5m2.5m

Current Liabilities

8.8m6.7m7.4m11.1m11.9m11.4m11.5m

Long-term debt

2.9m2.8m2.7m2.5m2.3m34.0k

Total Debt

561.3k581.4k4.5m7.3m5.3m5.2m2.5m2.3m34.0k

Total Liabilities

8.5m4.7m1.9m2.3m2.3m2.1m2.2m4.0m14.3m12.0m12.8m10.1m10.3m10.3m14.0m12.4m12.9m13.3m

Additional Paid-in Capital

34.1m54.7m58.7m63.9m76.3m77.1m77.7m84.1m96.2m112.6m115.1m133.0m152.0m155.1m156.7m198.0m201.7m203.4m

Retained Earnings

(39.1m)(44.6m)(49.0m)(51.1m)(58.6m)(62.2m)(65.4m)(75.4m)(81.1m)(87.8m)(94.2m)(99.2m)(106.0m)(121.6m)(131.3m)(140.2m)(161.9m)(169.6m)

Total Equity

9.7m12.8m17.7m14.8m12.3m8.7m15.0m24.8m20.9m33.8m46.0m33.4m25.4m57.8m39.8m33.8m

Debt to Equity Ratio

0.1 x0.1 x0 x

Debt to Assets Ratio

0.1 x0.1 x0 x

Financial Leverage

1.2 x1.2 x1.1 x1.1 x1.2 x1.5 x2 x1.5 x1.6 x1.3 x1.2 x1.3 x1.5 x1.2 x1.3 x1.4 x

Adamis Pharmaceuticals Cash Flow

Annual

USDFY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

Depreciation and Amortization

990.3k2.5m3.1m3.1m

Accounts Receivable

Inventories

14.5k(165.0k)1.9k(882.5k)(5.0m)

Accounts Payable

(1.8m)(289.2k)(1.7m)587.2k846.1k

Cash From Operating Activities

5.4m306.0k

Purchases of PP&E

(97.1k)(121.1k)(2.1m)(3.5m)

Cash From Investing Activities

(10.0m)260.7k(2.1m)(3.5m)

Short-term Borrowings

(38.7k)

Cash From Financing Activities

22.2m10.6m21.9m30.5m37.1m

Interest Paid

1.2m89.4k229.6k216.8k181.3k

Income Taxes Paid

2.4k19.0k16.7k5.6k

Quarterly

USDQ1, 2015Q2, 2015Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019

Depreciation and Amortization

495.1k247.6k966.6k1.8m782.6k1.6m2.3m770.9k1.5m2.3m791.9k1.5m

Accounts Receivable

744.7k595.6k1.2m

Inventories

(282.1k)(112.9k)27.9k(7.9k)(54.0k)(514.7k)(785.3k)(1.4m)(808.2k)(175.2k)

Accounts Payable

547.7k750.0k977.2k(289.0k)408.8k1.0m316.7k(2.1m)562.9k(256.5k)(400.3k)(1.1m)1.2m603.1k(66.3k)369.6k

Purchases of PP&E

(16.8k)(16.8k)(48.0k)(615.5k)(1.5m)(201.1k)(1.3m)(3.2m)(1.7m)(2.2m)

Cash From Investing Activities

365.0k(64.2k)(1.5m)(201.1k)(3.2m)(1.7m)

Cash From Financing Activities

10.6m5.0m7.1m21.2m(115.3k)14.3m30.6m(119.7k)37.3m(142.0k)

Interest Paid

175.5k39.7k130.9k182.8k50.4k108.8k156.1k24.4k47.0k

Income Taxes Paid

46.1k2.4k2.4k912.013.6k13.6k8.7k8.7k9.6k

Adamis Pharmaceuticals Ratios

USDY, 2019

Financial Leverage

1.4 x